Healthcare
Deal focus: Fourier brings robotics to rehab
China-based Fourier will use its USD 63m Series D round to support an evolution of its business model from manufacturing rehabilitation robots to providing end-to-end treatment services
Vision Fund backs China healthcare robotics player
Fourier Intelligence, a Shanghai-based medical technology start-up that focuses on rehabilitation robots, has raised CNY 400m (USD 63m) in Series D funding led by SoftBank Vision Fund 2.
Bond leads $43m Series C for Australia's Eucalyptus
Bond, a US-based technology investment firm established by Silicon Valley stalwart Mary Meeker, has led a AUD 60m (USD 43m) Series C round for Australian telehealth platform Eucalyptus.
China medtech start-up SiBionics raises $79m
China-based medical technology start-up SiBionics has raised CNY 500m (USD 79m) in a third tranche of Series C funding co-led by CPE and China Life Investment.
River Head Capital hits first close on latest reminbi fund
China’s River Head Capital has achieved a first close on its second Innovation Growth Fund, a renminbi-denominated vehicle that has an overall target of CNY 2bn (USD 135m).
CapVest tops BGH's bid for Australia's Virtus Health
CapVest Partners, a UK-headquartered private equity firm that primarily invests in Europe and North America, has entered the race for Australian fertility care business Virtus Health with an AUD 650.1m (USD 469m) offer.
TPG-owned clinical trials player raises new equity, debt
Novotech, an Asia-based clinical trials specialist controlled by TPG Capital, has secured USD 760m in new equity and debt financing at a post-deal valuation of approximately USD 3bn.
Quadria backs Vietnam mother-and-baby chain
Singapore-based healthcare specialist Quadria Capital has invested USD 90m in Con Cung, Vietnam’s largest mother-and-baby retailer.
Goldman, Sofina lead Series C for China CDMO Zhenge
Goldman Sachs Asset Management and Sofina have led a USD 100m Series C round for Zhenge Biotech, a Shanghai-based contract development and manufacturing organisation (CDMO).
Profile: Alkemi Growth Capital’s Alka Goel
A trail of haphazard jobs helped flesh out Alka Goel’s adventurousness and people skills before she established Indian healthcare and wellness specialist Alkemi Growth Capital
China gene therapy start-up Cure Genetics raises $60m
Advantech Capital has led a USD 60m Series B for Suzhou-based biotech player Cure Genetics. Other investors include Oriza Holdings, Blue Ocean Private Equity, and Qiming Venture Partners.
Singapore's Virtue Diagnostics closes $100m Series B
Singapore-based Virtue Diagnostics, a clinical testing equipment supplier for China and developing markets, has raised a USD 100m Series B round led by Sequoia Capital China and Morningside Ventures.
AGIC exits healthcare business Ritedose to Novo Holdings
AGIC Capital, which specializes in cross-border deals along the China-Europe axis, has agreed to sell pharmaceutical manufacturing and packaging business Ritedose Corporation to Novo Holdings.
China CDMO Thousand Oaks raises $240m
Thousand Oaks Biopharmaceuticals, a China-based contract development and manufacturing organization (CDMO), has raised CNY 1.5bn (USD 240m) in funding led by Goldstone Investment - a private equity unit of CITIC Securities - and CDH Investments.
China biotech player GenFleet raises $75m
GenFleet Therapeutics, a Chinese biotech developer focused on oncology and immunology, has secured a USD 75m Series C round led by Huagai Capital.
PE consortium backs New Zealand fertility business
Pioneer Capital, New Zealand Superannuation Fund, and Comprador Holdings have together acquired a 70% stake in Fertility Associates, a New Zealand-based fertility treatment provider.
Carlyle agrees $419m exit from Japan healthcare business
The Carlyle Group has agreed to sell Sunsho Pharmaceuticals, a Japan-based contract manufacturer of dietary supplements, to Towa Pharmaceutical for JPY47.7 billion ($419.5 million).
India's Pristyn Care raises $96m at $1.4b valuation
Pristyn Care, a clinic operator specializing in minimally evasive surgeries, has joined India’s unicorn boom with a $96 million Series E round featuring Sequoia Capital at a valuation of $1.4 billion.
Blackbird backs Australia 3D cell culture platform
Australia’s Blackbird Ventures has led a $25 million Series B round for Inventia Life Science, a local start-up that provides 3D cell cultures for research and clinical purposes.
Advent acquires China's largest medical capsule maker
Advent International has acquired a majority stake in Guangsheng Medicinal Capsule (GS Capsule), the largest medical capsule maker in China, for an undisclosed sum.
2022 preview: Healthcare
Healthcare’s high-cost, rapidly digitizing profile will persist regardless of how COVID-19 plays out in the coming years. China appears set for consolidation, including in biotech
BGH makes $432m bid for Australia's Virtus Health
BGH Capital has submitted a take-private bid for Virtus Health, an Australia-based fertility care services provider, that values the business at approximately A$607.3 million ($432 million).
China's Avistone Pharmaceuticals raises $200m
Avistone Pharmaceuticals, a Beijing biotech company focused on precision oncology therapeutics has raised more than $200 million in a Series A funding round led by Vivo Capital.
PEP sells Australia, New Zealand healthcare businesses
Pacific Equity Partners (PEP) has agreed two healthcare exits, with Australia-based medical devices distributor LifeHealthcare to be sold to Ebos Group and New Zealand corporate hospital platform Evolution Healthcare going to QIC and Sunsuper.